Wells Fargo’s Avenue Therapeutics, Inc. Common Stock ATXI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-500
| Closed | -$1K | – | 7338 |
|
|
2024
Q4 | $1K | Sell |
500
-61
| -11% | -$124 | ﹤0.01% | 6258 |
|
|
2024
Q3 | $1.4K | Buy |
561
+500
| +820% | +$1.43K | ﹤0.01% | 6091 |
|
|
2024
Q2 | $214 | Sell |
61
-3
| -5% | -$17 | ﹤0.01% | 6197 |
|
|
2024
Q1 | $709 | Buy |
64
+2
| +3% | +$24 | ﹤0.01% | 6227 |
|
|
2023
Q4 | $745 | Buy |
62
+1
| +2% | +$23 | ﹤0.01% | 6298 |
|
|
2023
Q3 | $3.24K | Hold |
61
| – | – | ﹤0.01% | 6022 |
|
|
2023
Q2 | $5.37K | Hold |
61
| – | – | ﹤0.01% | 6069 |
|
|
2023
Q1 | $5.32K | Hold |
61
| – | – | ﹤0.01% | 6036 |
|
|
2022
Q4 | $5.29K | Hold |
61
| – | – | ﹤0.01% | 5757 |
|
|
2022
Q3 | $46K | Hold |
61
| – | – | ﹤0.01% | 5004 |
|
|
2022
Q2 | $18K | Buy |
61
+18
| +42% | +$6.93K | ﹤0.01% | 5514 |
|
|
2022
Q1 | $23K | Hold |
43
| – | – | ﹤0.01% | 5971 |
|
|
2021
Q4 | $44K | Hold |
43
| – | – | ﹤0.01% | 6031 |
|
|
2021
Q3 | $72K | Buy |
+43
| New | +$88.9K | ﹤0.01% | 5503 |
|
|
2021
Q2 | – | Sell |
-3
| Closed | -$14.8K | – | 7592 |
|
|
2021
Q1 | $22K | Sell |
3
-12
| -80% | -$82.5K | ﹤0.01% | 6123 |
|
|
2020
Q4 | $98K | Sell |
15
-2
| -12% | -$10.5K | ﹤0.01% | 5371 |
|
|
2020
Q3 | $205K | Buy |
17
+6
| +55% | +$72.9K | ﹤0.01% | 4949 |
|
|
2020
Q2 | $128K | Buy |
+11
| New | +$124K | ﹤0.01% | 5111 |
|
|
2020
Q1 | – | Hold |
0
| – | – | – | 6947 |
|
|
2019
Q3 | – | Hold |
0
| – | – | – | 6798 |
|
|
2019
Q2 | – | Hold |
0
| – | – | – | 6675 |
|
Wells Fargo's ATXI Position: Q1 2025 in Review
Wells Fargo sold out of Avenue Therapeutics, Inc. Common Stock (ATXI) in Q1 2025, closing a stake of 500 shares — an estimated $1K sold.
Wells Fargo first reported a position in ATXI in Q2 2020 and held it in 18 quarters. The position peaked at $205K in Q3 2020. 0 funds tracked by Wall St. Rank hold ATXI as of Q1 2025.
- Wells Fargo reported no remaining Avenue Therapeutics, Inc. Common Stock position as of Q1 2025 after selling out during the quarter.
- Wells Fargo sold 500 Avenue Therapeutics, Inc. Common Stock shares in Q1 2025, an estimated $1K.
- Wells Fargo first reported a position in Avenue Therapeutics, Inc. Common Stock in Q2 2020 and held it in 18 quarters.
- Wells Fargo's Avenue Therapeutics, Inc. Common Stock position peaked at $205K in Q3 2020.
- 0 funds tracked by Wall St. Rank held Avenue Therapeutics, Inc. Common Stock as of Q1 2025.
Based on Wells Fargo's 13F filing for Q1 2025, filed 13 May 2025.